Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SUTRO BIOPHARMA, INC.STRO · Entity 5797 | Director · Chief Executive Officer | March 04, 2026 | March 06, 2026 |
| Viracta Therapeutics, Inc.VIRX · Entity 85616 | Director | June 20, 2024 | June 24, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SUTRO BIOPHARMA, INC.
Report date March 04, 2026 · Filed March 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,285 |
Ending reported balance
After 2026-03-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-04 · Exercise / conversion · Acquired 788 · Balance 21,567 Row 2 · 2026-03-04 · Tax withholding · Disposed 282 · Balance 21,285 F1: Represents the number of shares of Common Stock that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. |
| Restricted Stock Units (RSUs)SEC Table II · derivative / convertible security · Expires 2026-03-04 | Direct | 0 |
Reported balance
After 2026-03-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-03-04 · Exercise / conversion · Disposed 788 · Balance 0 F2: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F3: The RSUs vested or vest as to 1/4 of the total award annually, with the first tranche vested on March 4, 2023, subject to continued service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of Common Stock that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person.
F2: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.
F3: The RSUs vested or vest as to 1/4 of the total award annually, with the first tranche vested on March 4, 2023, subject to continued service through each vesting date.
Viracta Therapeutics, Inc.
Report date June 20, 2024 · Filed June 24, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.57 · Expires 2034-06-20 | Direct | 50,000 |
Reported balance
After 2024-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-20 · Grant · Acquired 50,000 · Balance 50,000 F1: 1/12th of the shares subject to the option shall vest each month following the date of grant, or if earlier 100% of the shares subject to the option shall vest on the date of the Issuer's next annual stockholder meeting, in each case subject to the reporting person remaining a Service Provider (as defined in the 2021 Equity Incentive Plan) through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/12th of the shares subject to the option shall vest each month following the date of grant, or if earlier 100% of the shares subject to the option shall vest on the date of the Issuer's next annual stockholder meeting, in each case subject to the reporting person remaining a Service Provider (as defined in the 2021 Equity Incentive Plan) through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 04, 2026 Filed Mar 6, 2026 16:21 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Units (RSUs) · Derivative | 788 | $0.00 | $0.00 |
DisclosureSEC source: 0001872398-26-000003 · form4-03062026_090306.xml · derivative · entry 3 Chung Jane · CIK 0001872398 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 788 shares Expires 2026-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vested or vest as to 1/4 of the total award annually, with the first tranche vested on March 4, 2023, subject to continued service through each vesting date. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 16:21 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 282 | $21.31 | $6,009.42 |
DisclosureSEC source: 0001872398-26-000003 · form4-03062026_090306.xml · nonDerivative · entry 2 Chung Jane · CIK 0001872398 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,285 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 16:21 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 788 | $0.00 | $0.00 |
DisclosureSEC source: 0001872398-26-000003 · form4-03062026_090306.xml · nonDerivative · entry 1 Chung Jane · CIK 0001872398 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,567 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 18:48 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $20.55 | $0.00 |
DisclosureSEC source: 0001872398-26-000002 · form4-03032026_110347.xml · derivative · entry 10 Chung Jane · CIK 0001872398 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2036-03-02 F7 · derivative.exercise_date: 1/48 of the total option award shall vest monthly, subject to the reporting person's continued service through each vesting date, with the first tranche vesting on April 1, 2026. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 18:48 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Units (RSUs) · Derivative | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001872398-26-000002 · form4-03032026_110347.xml · derivative · entry 9 Chung Jane · CIK 0001872398 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-03-01 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F6 · derivative.exercise_date: The RSUs shall vest as to 1/4 of the total award annually, with the first tranche vesting on March 1, 2027, subject to continued service through each vesting date. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 18:48 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Units (RSUs) · Derivative | 7,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001872398-26-000002 · form4-03032026_110347.xml · derivative · entry 8 Chung Jane · CIK 0001872398 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,250 Underlying: Common Stock · 7,750 shares Expires 2029-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F5 · derivative.exercise_date: The RSUs vested or vest as to 1/4 of the total award annually, with the first tranche vested on March 2, 2026, subject to continued service through each vesting date. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 18:48 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 2,779 | $20.55 | $57,108.45 |
DisclosureSEC source: 0001872398-26-000002 · form4-03032026_110347.xml · nonDerivative · entry 5 Chung Jane · CIK 0001872398 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,779 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 18:48 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 7,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001872398-26-000002 · form4-03032026_110347.xml · nonDerivative · entry 4 Chung Jane · CIK 0001872398 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,558 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 18:48 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Units (RSUs) · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001872398-26-000002 · form4-03032026_110347.xml · derivative · entry 7 Chung Jane · CIK 0001872398 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 2,500 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The RSUs vested or vest as to 1/4 of the total award annually, with the first tranche vested on March 1, 2025, subject to continued service through each vesting date. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 18:48 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Units (RSUs) · Derivative | 688 | $0.00 | $0.00 |
DisclosureSEC source: 0001872398-26-000002 · form4-03032026_110347.xml · derivative · entry 6 Chung Jane · CIK 0001872398 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 688 Underlying: Common Stock · 688 shares Expires 2027-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vested or vest as to 1/4 of the total award annually, with the first tranche vested on March 1, 2024, subject to continued service through each vesting date. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 18:48 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 1,271 | $20.47 | $26,017.37 |
DisclosureSEC source: 0001872398-26-000002 · form4-03032026_110347.xml · nonDerivative · entry 3 Chung Jane · CIK 0001872398 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,808 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 18:48 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001872398-26-000002 · form4-03032026_110347.xml · nonDerivative · entry 2 Chung Jane · CIK 0001872398 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,079 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 18:48 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 688 | $0.00 | $0.00 |
DisclosureSEC source: 0001872398-26-000002 · form4-03032026_110347.xml · nonDerivative · entry 1 Chung Jane · CIK 0001872398 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,579 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 20:47 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001872398-25-000005 · form4-12172025_011222.xml · derivative · entry 3 Chung Jane · CIK 0001872398 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 2,500 shares Expires 2027-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSU award vested or vests as to 1/4th of the total award annually, subject to continued service through each vesting date, with the first tranche vested on December 1, 2024. The reported transaction represents the deferred vesting and settlement of a tranche of this award pursuant to the terms of the reporting person's award agreement with the Issuer. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 20:47 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 894 | $8.02 | $7,165.41 |
DisclosureSEC source: 0001872398-25-000005 · form4-12172025_011222.xml · nonDerivative · entry 2 Chung Jane · CIK 0001872398 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,891 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs; does not represent a sale by the reporting person. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 20:47 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001872398-25-000005 · form4-12172025_011222.xml · nonDerivative · entry 1 Chung Jane · CIK 0001872398 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,785 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 15, 2025 Filed Oct 16, 2025 08:17 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | PurchaseCommon Stock | 12,500 | $0.80 | $10,011.25 |
DisclosureSEC source: 0001872398-25-000004 · form4-10162025_121000.xml · nonDerivative · entry 1 Chung Jane · CIK 0001872398 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,850 Read SEC document |
| August 09, 2025 Filed Aug 26, 2025 21:20 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-023083 · form4-08272025_010839.xml · derivative · entry 3 Chung Jane · CIK 0001872398 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,750 shares Expires 2025-08-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vested or vest as to 1/4th of the total award annually beginning on August 9, 2022, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| August 09, 2025 Filed Aug 26, 2025 21:20 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 6,708 | $0.80 | $5,366.40 |
DisclosureSEC source: 0001415889-25-023083 · form4-08272025_010839.xml · nonDerivative · entry 2 Chung Jane · CIK 0001872398 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,350 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. Read SEC document |
| August 09, 2025 Filed Aug 26, 2025 21:20 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-023083 · form4-08272025_010839.xml · nonDerivative · entry 1 Chung Jane · CIK 0001872398 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,058 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 04, 2025 Filed Apr 8, 2025 16:12 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Units (RSUs) · Derivative | 310,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-010385 · form4-04082025_080404.xml · derivative · entry 2 Chung Jane · CIK 0001872398 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 310,000 Underlying: Common Stock · 310,000 shares Expires 2029-03-02 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total award annually beginning on March 2, 2026, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| April 04, 2025 Filed Apr 8, 2025 16:12 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (Right to Buy) · Derivative | 620,000 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0001415889-25-010385 · form4-04082025_080404.xml · derivative · entry 1 Chung Jane · CIK 0001872398 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 620,000 Underlying: Common Stock · 620,000 shares Expires 2035-04-04 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total award monthly, beginning on May 4, 2025, with 100% of the award being vested and exercisable on April 4, 2029, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 16:06 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 7,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-007182 · form4-03062025_090350.xml · derivative · entry 3 Chung Jane · CIK 0001872398 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,875 Underlying: Common Stock · 7,875 shares Expires 2026-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total award annually beginning on March 4, 2023, subject to continued service through each vesting date. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 16:06 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 2,334 | $1.42 | $3,314.28 |
DisclosureSEC source: 0001415889-25-007182 · form4-03062025_090350.xml · nonDerivative · entry 2 Chung Jane · CIK 0001872398 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,308 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 16:06 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 7,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-007182 · form4-03062025_090350.xml · nonDerivative · entry 1 Chung Jane · CIK 0001872398 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,642 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 18:42 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006712 · form4-03042025_110302.xml · derivative · entry 5 Chung Jane · CIK 0001872398 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 25,000 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The RSUs vest as to 1/4th of the total award annually beginning on March 1, 2025, subject to continued service through each vesting date. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 18:42 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 6,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006712 · form4-03042025_110302.xml · derivative · entry 4 Chung Jane · CIK 0001872398 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,750 Underlying: Common Stock · 6,875 shares Expires 2027-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on March 1, 2024, subject to continued service through each vesting date. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 18:42 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 9,450 | $1.59 | $15,025.50 |
DisclosureSEC source: 0001415889-25-006712 · form4-03042025_110302.xml · nonDerivative · entry 3 Chung Jane · CIK 0001872398 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,767 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 18:42 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006712 · form4-03042025_110302.xml · nonDerivative · entry 2 Chung Jane · CIK 0001872398 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,217 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 18:42 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 6,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006712 · form4-03042025_110302.xml · nonDerivative · entry 1 Chung Jane · CIK 0001872398 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,217 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2024 Filed Dec 3, 2024 16:09 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-028066 · form4-12032024_091242.xml · derivative · entry 3 Chung Jane · CIK 0001872398 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 25,000 shares Expires 2027-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on December 1, 2024, subject to continued service through each vesting date. Read SEC document |
| December 01, 2024 Filed Dec 3, 2024 16:09 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 8,920 | $2.69 | $23,994.80 |
DisclosureSEC source: 0001415889-24-028066 · form4-12032024_091242.xml · nonDerivative · entry 2 Chung Jane · CIK 0001872398 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,342 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. Read SEC document |
| December 01, 2024 Filed Dec 3, 2024 16:09 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-028066 · form4-12032024_091242.xml · nonDerivative · entry 1 Chung Jane · CIK 0001872398 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,262 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2024 Filed Aug 13, 2024 16:16 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-021157 · form4-08132024_080852.xml · derivative · entry 3 Chung Jane · CIK 0001872398 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 18,750 shares Expires 2025-08-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vested or vest as to 1/4th of the total award annually beginning on August 9, 2022, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| August 09, 2024 Filed Aug 13, 2024 16:16 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 6,689 | $3.12 | $20,869.68 |
DisclosureSEC source: 0001415889-24-021157 · form4-08132024_080852.xml · nonDerivative · entry 2 Chung Jane · CIK 0001872398 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,262 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. Read SEC document |
| August 09, 2024 Filed Aug 13, 2024 16:16 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-021157 · form4-08132024_080852.xml · nonDerivative · entry 1 Chung Jane · CIK 0001872398 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,951 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 19:48 UTC | Viracta Therapeutics, Inc. VIRX · Entity 85616 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0000950170-24-077005 · ownership.xml · derivative · entry 1 Chung Jane · CIK 0001872398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-06-20 F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest each month following the date of grant, or if earlier 100% of the shares subject to the option shall vest on the date of the Issuer's next annual stockholder meeting, in each case subject to the reporting person remaining a Service Provider (as defined in the 2021 Equity Incentive Plan) through the applicable vesting date. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 16:26 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Units (RSUs) · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-007183 · form4-03072024_090340.xml · derivative · entry 2 Chung Jane · CIK 0001872398 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-03-01 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total award annually beginning on March 1, 2025, subject to continued service through each vesting date. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 16:26 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (Right to Buy Common Stock) · Derivative | 50,000 | $0.00 Strike: $4.54 | $0.00 |
DisclosureSEC source: 0001415889-24-007183 · form4-03072024_090340.xml · derivative · entry 1 Chung Jane · CIK 0001872398 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-03-05 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total award monthly, beginning on April 1, 2024, with 100% of the award being vested and exercisable on March 1, 2028, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 16:21 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 7,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-007020 · form4-03062024_090325.xml · derivative · entry 3 Chung Jane · CIK 0001872398 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,750 Underlying: Common Stock · 7,875 shares Expires 2026-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total award annually beginning on March 4, 2023, subject to continued service through each vesting date. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 16:21 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 2,209 | $4.79 | $10,581.11 |
DisclosureSEC source: 0001415889-24-007020 · form4-03062024_090325.xml · nonDerivative · entry 2 Chung Jane · CIK 0001872398 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,201 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 16:21 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 7,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-007020 · form4-03062024_090325.xml · nonDerivative · entry 1 Chung Jane · CIK 0001872398 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,410 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 16:32 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 6,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-006687 · form4-03052024_090320.xml · derivative · entry 3 Chung Jane · CIK 0001872398 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,625 Underlying: Common Stock · 6,875 shares Expires 2027-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSU award vests as to 1/4th of the total award annually beginning on March 1, 2024, subject to continued service through each vesting date. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 16:32 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 2,038 | $4.95 | $10,088.10 |
DisclosureSEC source: 0001415889-24-006687 · form4-03052024_090320.xml · nonDerivative · entry 2 Chung Jane · CIK 0001872398 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,535 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 16:32 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 6,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-006687 · form4-03052024_090320.xml · nonDerivative · entry 1 Chung Jane · CIK 0001872398 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,573 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2023 Filed Dec 4, 2023 16:19 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Unit (RSU) · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-057206 · doc4.xml · derivative · entry 2 Chung Jane · CIK 0001872398 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2027-12-01 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on December 1, 2024, subject to continued service through each vesting date. Read SEC document |
| December 01, 2023 Filed Dec 4, 2023 16:19 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0001209191-23-057206 · doc4.xml · derivative · entry 1 Chung Jane · CIK 0001872398 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2033-12-01 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning on January 1, 2024, with 100% of the total shares vested and exercisable on December 1, 2027, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| August 09, 2023 Filed Aug 11, 2023 16:16 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-045434 · doc4.xml · derivative · entry 3 Chung Jane · CIK 0001872398 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 18,750 shares Expires 2025-08-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on August 9, 2022, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| August 09, 2023 Filed Aug 11, 2023 16:16 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 6,483 | $4.22 | $27,358.26 |
DisclosureSEC source: 0001209191-23-045434 · doc4.xml · nonDerivative · entry 2 Chung Jane · CIK 0001872398 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,698 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| August 09, 2023 Filed Aug 11, 2023 16:16 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-045434 · doc4.xml · nonDerivative · entry 1 Chung Jane · CIK 0001872398 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,181 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.